LLY stock: buy or sell?

LLY stock price: $116.16 1.58% At close on September 20th, 2019

Updated on:
September 20th, 2019

4

Eli Lilly and broke up the SMA line of 200d today and closed at $116.16. Counting Friday, it's been 4 green days in a row, gaining $6.03 or 5.44%.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products.

Should I buy LLY stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Check the only buy setup that matches with Eli Lilly and stock now:

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MAYes
100d MA crossing up 200d MANo

Is Eli Lilly and stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we gathered 9 ratings published for LLY stock in the last month.

The general sentiment of these ratings is bullish for LLY stock, with 5 positive ratings.
Is LLY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-10Bank of American/aNeutral
2019-5-28Goldman Sachs Groupn/aBuy
2019-3-22Credit Suisse Groupn/aHold
2019-3-20UBS Groupn/aBuy
2019-3-12JPMorgan Chase & Co.OverweightOverweight
2019-2-8UBS Groupn/aAverage
2019-2-8UBS Groupn/aAverage
2019-2-4Cantor Fitzgeraldn/aBuy
2019-1-23UBS Groupn/aBuy

LLY stock analysis

Daily outlook

Eli Lilly and shares broke up the SMA line of 200 days today and closed at $116.16.

Eli Lilly and broke up the SMA line of 200 days today and closed at $116.16. LLY broke out again over $112.42 after a 2.86% correction started on Sep/12.

LLY stock chart (daily)

Weekly outlook

Eli Lilly and shares crossed up the SMA line of 200d, closing at $116.16.

If you observe the weekly chart, price finally broke over the resistance at $115.49 and continued climbing. Far behind is the all-time high Eli Lilly and hit late March and since then the price is -11.10% below that top.

LLY stock chart (weekly)

LLY stock price history

LLY stock historical price chart

LLY stock reached all-time highs on March with a price of $130.66.

LLY stock price target is $119.30

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 6 price predictions for Eli Lilly and stock:
LLY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-10Bank of AmericaReiterates$118.00$120.001.7%
2019-5-28Goldman Sachs GroupInitiatesn/a$135.00-
2019-3-22Credit Suisse GroupSet Price Targetn/a$121.00-
2019-3-12JPMorgan Chase & Co.Initiatesn/a$140.00-
2019-2-8UBS GroupReiterates$107.53$100.00-7%
2019-2-8UBS GroupLowers Target$107.53$100.00-7%
(in average)$111.00$119.307.0%
The price target for Eli Lilly and stock is $119.30, moving in a range between $140.00 and $100.00. In average, analysts' outlook on LLY price target is positive, upgrading the target by a 7.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on April, Eli Lilly and . Unfortunately, reported EPS is not yet available in our database.
LLY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a0.99n/a
2017-Q32017-10-241.031.051.9%
2017-Q42018-01-311.071.146.5%
2018-Q12018-04-241.131.3418.6%
2018-Q22018-07-241.311.514.5%
2018-Q32018-11-061.371.391.5%
2018-Q42019-02-061.361.33-2.2%
2019-Q12019-04-301.31n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a great growth of 7.36% to $24,555.70 M dollars. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) skyrocketed a 14.05% to 13.16%.

To have an updated picture of the financial situation of Eli Lilly and, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Eli Lilly and TTM sales up to March 2019 were $23,947.90 and income was $6,256.20 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Eli Lilly and business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, decreased an unpleasant -2.48%. Regarding profit margin, Eli Lilly and rocketed 12.96% to 13.16%

LLY annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$23,110 M-$4,680 M20.3%-
2014$19,616 M-15.12%$2,391 M12.2%-48.92%
2015$19,959 M1.75%$2,408 M12.1%0.75%
2016$21,222 M6.33%$2,738 M12.9%13.67%
2017$22,871 M7.77%$-204.10 M-0.9%-107.46%
2018$24,556 M7.36%$3,232 M13.2%-1,683.54%
TTM $23,948 M-2.48%$6,256 M26.1%93.57%

Quarterly financial results

Eli Lilly and reported $5,092.20 M in revenues for 2019-Q1, a -20.91% less compared to previous quarter. Reported quarter income marked $4,241.60 M with a profit margin of 83.30%. Profit margin boosted a 65.82% compared to previous quarter when profit margin was 17.47%. When comparing turnover to same quarter last year, Eli Lilly and sales marked a horrible decrease and plummed a -10.66%.
LLY quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$5,820 M-$1,010 M17.4%-
2017-Q3$5,658 M-2.78%$556 M9.8%-44.99%
2017-Q4$6,161 M8.88%$-1,657 M-26.9%-398.22%
2018-Q1$5,700 M-7.48%$1,217 M21.4%-173.47%
2018-Q2$6,355 M11.49%$-260 M-4.1%-121.35%
2018-Q3$6,062 M-4.62%$1,150 M19.0%-542.29%
2018-Q4$6,439 M6.21%$1,125 M17.5%-2.13%
2019-Q1$5,092 M-20.91%$4,242 M83.3%277.03%

Eli Lilly and ownership

When you are planning to buy a company, it's always worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Eli Lilly and, 0.12% of all outstanding shares are owned by its staff.

Bearish positions for LLY stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

LLYABBVAMGNBMYGSK
Market cap$112.1 B$106.1 B$118.1 B$82.9 B$103.7 B
Total shares965.4 M1,480.0 M599.7 M1,640.0 M2,490.0 M
Float shares796.2 M1,480.0 M598.3 M1,630.0 M2,450.0 M
  - Institutional holdings (%)81.5%71.9%81.9%75.0%11.0%
  - Insider holdings (%)0.1%0.1%0.2%0.1%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

LLY summary

Friday, September 20th, 2019
Open$115.93
Close$116.16
Day range$114.47 - $117.23
Previous close$114.35
Session gain1.58%
Average true range$2.26
50d mov avg$110.68
100d mov avg$112.47
200d mov avg$115.45
Daily patternlb01c
Weekly pattern lb01c

Eli Lilly and performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Eli Lilly and performance to AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Novartis, Pfizer and :
Stock3m6m12m
LLYEli Lilly and1.14%-8.44%11.63%
ABBVAbbVie-7.64%-7.56%-18.24%
AMGNAmgen6.00%7.15%-1.03%
BMYBristol-Myers Squ...3.39%6.87%-16.14%
GSKGlaxoSmithKline4.57%3.33%8.61%
JNJ-7.74%-3.60%-6.42%
MRKMerck1.38%4.89%23.08%
NVSNovartis-5.90%3.97%17.32%
PFEPfizer-15.62%-11.17%-14.22%
SNY5.23%9.34%11.12%

Eli Lilly and competitors

We chose a few stocks to conform a list of Eli Lilly and competitors to watch if you are interested in investing in LLY:

Latest LLY stock news